Clinical Trial Update: JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of JAG201 Gene Therapy for SHANK3 haploinsufficiency and Phelan-McDermid syndrome, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phelan-mcdermid Syndrome
• Shank3 Haploinsufficiency

Drugs mentioned

• JAG201 Gene Therapy

Snippet

Sponsor: Jaguar Gene Therapy, LLC | Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome | Phase 1, Phase 2 | Status: RECRUITING